The Future of Acquired TTP
X. Long Zheng, MD, PhD, discusses the unmet needs of acquired TTP, and the future of treatment.
Treatment Considerations for Caplacizumab
X. Long Zheng, MD, PhD, explains when physicians should administer caplacizumab after suspecting a diagnosis of acquired TTP, and discusses the risk of relapse or refractory disease.
Using Caplacizumab to Treat Acquired TTP
An expert in acquired TTP describes the use of caplacizumab in treating acquired TTP, and highlights data from a phase III clinical trial.
Treatment Options for Acquired TTP
X. Long Zheng, MD, PhD, details the typical healthcare costs for acquired TTP, the treatment options available to patients, and the goals of the healthcare provider.
Diagnostic Approach to Acquired TTP
A key opinion leader explains how acquired TTP is diagnosed, with a focus on the use of ADAMTS13 testing.
Overview of Acquired Thrombotic Thrombocytopenic Purpura
X. Long Zheng, MD, PhD, gives an overview on acquired thrombotic thrombocytopenic purpura including prevalence and the typical patient presentation.
